Linked Life Data

19886361

Source:http://linkedlifedata.com/resource/pubmed/id/19886361

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-11-5
pubmed:abstractText
Recently, research at genetic and molecular levels has extensively accelerated due to advances in new technologies. Since the mid-90s, a relatively new discipline--clinical proteomics, has evolved, which focuses on studying gene products--proteins. The evaluation of protein profiles may contribute to the more accurate stratification of patients in the future, in terms of both prediction of treatment results and prognosis. In pursuing this objective, proteomic approaches are currently used for the identification of new biomarkers. This is also the case with malignant melanoma, a disease without typical serum marker possessing high sensitivity and high specificity.
pubmed:language
cze
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0862-495X
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
228-32
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
[Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study].
pubmed:affiliation
Klinika komplexní onkologické péce, Masaryk?v onkologicky ustav, Brno. lakomy@mou.cz
pubmed:publicationType
Journal Article, English Abstract